Mehmet Tughan Kiziltug is an accomplished researcher in molecular medicine and gene therapy, with a robust academic background and extensive experience in genetic disease research. Currently pursuing a second Ph.D. in Genomic and Molecular Medicine at Ludwig-Maximilians-Universität (LMU) Munich, Germany (2020–present, expected graduation October 2026), Mehmet specializes in gene therapy using induced pluripotent stem cells (iPSCs) and hematopoietic stem cells (HSCs), focusing on adeno-associated virus (AAV) and lentiviral vector systems. His research emphasizes capsid engineering for AAV vectors and next-generation targeted pseudotyped lentiviruses to enhance the precision and efficacy of gene delivery for therapeutic applications.
Mehmet Tughan Kiziltug is an accomplished researcher in molecular medicine and gene therapy, with a robust academic background and extensive experience in genetic disease research. Currently pursuing a second Ph.D. in Genomic and Molecular Medicine at Ludwig-Maximilians-Universität (LMU) Munich, Germany (2020–present, expected graduation October 2026), Mehmet specializes in gene therapy using induced pluripotent stem cells (iPSCs) and hematopoietic stem cells (HSCs), focusing on adeno-associated virus (AAV) and lentiviral vector systems. His research emphasizes capsid engineering for AAV vectors and next-generation targeted pseudotyped lentiviruses to enhance the precision and efficacy of gene delivery for therapeutic applications.